Ronglai Shen

Molecular Biology · 2003–2019

A researcher in the Science corpus: 31 papers; trusts 2 researchers and is trusted by 11 researchers here, as inferred from the citation graph.

Subfields

Molecular Biology — 392 citations into it; #5,739 of 17,773 by trust here, #352 by citations
Genetics — 197 citations into it; #3,651 of 6,854 by trust here, #507 by citations

Whom Ronglai Shen trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

Who trusts Ronglai Shen overall

Papers from Ronglai Shen's perspective

Ordered by how strongly the researchers Ronglai Shen trusts endorse each paper. Same corpus, a different order for every researcher.

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers (Genome Biology)
A CENSUS OF HUMAN CANCER GENES (Nature Reviews. Cancer)
Discovery and saturation analysis of cancer genes across 21 tumor types (Nature)
Highly recurrent TERT promoter mutations in human melanoma (Science)
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer (Nature Genetics)
The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity (Nature)
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 (Cancer Cell)
The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer (Nature)
Systematic identification of genomic markers of drug sensitivity in cancer cells (Nature)

Their papers

Comprehensive molecular portraits of human breast tumors (2012) — 7,518 citations
Comprehensive Molecular Characterization of Human Colon and Rectal Cancer (2012) — 7,754 citations
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis (2009) — 815 citations
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells (2003) — 1,715 citations
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer (2018) — 2,163 citations
Pattern discovery and cancer gene identification in integrated cancer genomic data (2013) — 424 citations
Integrated Genomic Analyses of Ovarian Carcinoma (2011) — 7,559 citations
Comprehensive molecular profiling of lung adenocarcinoma (2014) — 5,176 citations
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma (2011) — 668 citations
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma (2016) — 687 citations
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases (2004) — 646 citations
Autoantibody signatures in prostate cancer. (2005) — 611 citations
Genomic Classification of Cutaneous Melanoma (2015) — 2,764 citations
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017) — 2,216 citations
Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) — 2,692 citations
Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma (2014) — 2,001 citations
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants (2019) — 647 citations
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers (2018) — 851 citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types (2019) — 3,368 citations
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (2018) — 1,176 citations